Baird Financial Group Inc. Sells 5,819 Shares of Eli Lilly and Company (NYSE:LLY)

Baird Financial Group Inc. lessened its stake in shares of Eli Lilly and Company (NYSE:LLYGet Rating) by 2.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 257,810 shares of the company’s stock after selling 5,819 shares during the quarter. Baird Financial Group Inc.’s holdings in Eli Lilly and were worth $73,831,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of LLY. Vanguard Group Inc. boosted its position in shares of Eli Lilly and by 1.8% in the 1st quarter. Vanguard Group Inc. now owns 70,481,178 shares of the company’s stock worth $20,183,695,000 after purchasing an additional 1,219,424 shares in the last quarter. State Street Corp boosted its position in shares of Eli Lilly and by 2.5% in the 4th quarter. State Street Corp now owns 33,929,864 shares of the company’s stock worth $9,372,107,000 after purchasing an additional 813,983 shares in the last quarter. Capital World Investors boosted its position in shares of Eli Lilly and by 13.9% in the 4th quarter. Capital World Investors now owns 19,115,896 shares of the company’s stock worth $5,280,206,000 after purchasing an additional 2,325,514 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Eli Lilly and by 2.9% in the 4th quarter. Geode Capital Management LLC now owns 14,731,168 shares of the company’s stock worth $4,059,130,000 after purchasing an additional 409,009 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of Eli Lilly and in the 4th quarter worth $2,213,765,000. Institutional investors own 82.45% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on LLY shares. Morgan Stanley raised their price objective on Eli Lilly and from $395.00 to $412.00 and gave the stock an “overweight” rating in a research report on Wednesday. BMO Capital Markets raised their target price on Eli Lilly and from $369.00 to $396.00 and gave the stock an “outperform” rating in a research note on Tuesday. SVB Leerink initiated coverage on Eli Lilly and in a research note on Monday, May 23rd. They issued an “outperform” rating and a $341.00 target price for the company. Barclays raised their target price on Eli Lilly and from $333.00 to $355.00 and gave the stock an “overweight” rating in a research note on Thursday, July 7th. Finally, Citigroup raised their target price on Eli Lilly and from $285.00 to $370.00 in a research note on Thursday, August 25th. Three research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $330.44.

Insider Activity at Eli Lilly and

In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of Eli Lilly and stock in a transaction dated Wednesday, June 22nd. The stock was sold at an average price of $306.84, for a total value of $64,436,400.00. Following the sale, the insider now directly owns 104,623,810 shares in the company, valued at approximately $32,102,769,860.40. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of Eli Lilly and stock in a transaction dated Wednesday, June 22nd. The stock was sold at an average price of $306.84, for a total value of $64,436,400.00. Following the sale, the insider now directly owns 104,623,810 shares in the company, valued at approximately $32,102,769,860.40. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jackson P. Tai acquired 656 shares of the stock in a transaction that occurred on Friday, August 12th. The stock was purchased at an average price of $304.19 per share, for a total transaction of $199,548.64. Following the completion of the acquisition, the director now owns 62,857 shares in the company, valued at approximately $19,120,470.83. The disclosure for this purchase can be found here. Insiders sold a total of 753,125 shares of company stock worth $242,744,201 in the last 90 days. Corporate insiders own 0.12% of the company’s stock.

Eli Lilly and Price Performance

Shares of Eli Lilly and stock opened at $315.50 on Friday. The company has a quick ratio of 0.85, a current ratio of 1.10 and a debt-to-equity ratio of 1.70. Eli Lilly and Company has a twelve month low of $220.20 and a twelve month high of $335.33. The business has a 50-day moving average price of $318.08 and a 200 day moving average price of $300.47. The firm has a market cap of $299.78 billion, a PE ratio of 50.32, a P/E/G ratio of 2.13 and a beta of 0.38.

Eli Lilly and (NYSE:LLYGet Rating) last announced its quarterly earnings results on Thursday, August 4th. The company reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.86 by ($0.61). Eli Lilly and had a net margin of 19.58% and a return on equity of 85.58%. The business had revenue of $6.49 billion during the quarter, compared to analysts’ expectations of $6.85 billion. During the same quarter in the prior year, the firm earned $1.87 EPS. Eli Lilly and’s revenue for the quarter was down 3.7% on a year-over-year basis. Sell-side analysts predict that Eli Lilly and Company will post 7.96 earnings per share for the current fiscal year.

Eli Lilly and Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 9th. Investors of record on Monday, August 15th will be paid a $0.98 dividend. The ex-dividend date of this dividend is Friday, August 12th. This represents a $3.92 annualized dividend and a dividend yield of 1.24%. Eli Lilly and’s dividend payout ratio is presently 62.52%.

Eli Lilly and Company Profile

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Read More

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.